Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX

Haemophilia

Volumn 16, Issue 5, 2010, Pages 840-841

  Barnes, C ^a   Davis, A ^a   Furmedge, J ^a   Egan, B ^a   Donnan, L ^a   Monagle, P ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9 INHIBITOR; CORTICOSTEROID; MONOFIX; PROTEIN INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIBODY TITER; CASE REPORT; CHEMOPROPHYLAXIS; CHILD; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; FACE EDEMA; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; LETTER; LIMB DEFORMITY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ANAPHYLAXIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; DESENSITIZATION, IMMUNOLOGIC; FACTOR IX; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; TREATMENT OUTCOME;

EID: 77955939405     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01446.x     Document Type: Letter

References (5)

1. Warrier I. Antibodies to factor IX. Haematologica 2000, 85(Suppl.):31-3. discussion 33-4
2. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002, 87:52-7. North American Immune Tolerance Study G
3. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004, 55:477-503.
4. Mateo J, Badell I, Forner R, Borrell M, Tizzano E, Fontcuberta J. Successful suppression using rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs. Thromb Haemost 2006, 95:386-7.
5. Carcao M, St Louis J, Poon MC. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006, 12:7-18.